688314.SH
康拓医疗
SSE · Healthcare · Medical - Devices · CN
CNY 30.76
−5.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 342.3M | 351.1M | 321.9M | 275.0M | 239.9M |
| Cost of Revenue | 73.6M | 74.8M | 64.5M | 51.8M | 44.5M |
| Gross Profit | 268.6M | 276.3M | 257.5M | 223.3M | 195.5M |
| Operating Expenses | |||||
| R&D Expense | 29.9M | 25.6M | 23.9M | 17.6M | 18.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 60.7M | 56.5M | 56.0M | 52.3M | 44.1M |
| Selling & Marketing Expense | 65.8M | 64.7M | 63.7M | 55.1M | 47.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 163.0M | 152.4M | 146.4M | 126.4M | 110.1M |
| Cost and Expenses | 236.6M | 227.3M | 210.8M | 178.2M | 154.6M |
| Operating Income (EBIT) | 95.4M | 110.7M | 105.7M | 91.4M | 86.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 100.3M | 115.5M | 106.0M | 91.8M | 88.5M |
| Income Tax Expense | 13.5M | 17.8M | 18.4M | 17.3M | 14.3M |
| Bottom Line | |||||
| Net Income | 87.8M | 98.7M | 88.4M | 75.5M | 75.7M |
| Earnings from Cont. Ops | 86.7M | 97.7M | 87.6M | 74.5M | 74.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 87.8M | 98.7M | 88.4M | 75.5M | 75.7M |
| Per Share | |||||
| Basic EPS | CN¥1.08 | CN¥1.21 | CN¥1.09 | CN¥0.93 | CN¥0.93 |
| Diluted EPS | CN¥1.08 | CN¥1.21 | CN¥1.09 | CN¥0.93 | CN¥0.93 |
| Revenue Per Share | CN¥4.16 | CN¥4.30 | CN¥3.97 | CN¥3.39 | CN¥2.95 |
| Shares | |||||
| Basic Shares Outstanding | 82.2M | 81.6M | 81.1M | 81.2M | 81.4M |
| Diluted Shares Outstanding | 82.2M | 81.6M | 81.1M | 81.2M | 81.4M |
| Profitability Metrics | |||||
| EBITDA | — | 125.8M | 120.7M | 104.9M | 98.9M |
| D&A | — | 15.1M | 14.9M | 13.5M | 12.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026